OVERVIEW

Overcoming Barriers to Biologic Therapy in CRSwNP Through Collaborative Evidence-Based Care is organized by Integrity Continuing Education Inc. and will be held on Jan 06, 2026.

Description:
Key challenges remain in managing chronic rhinosinusitis with nasal polyps (CRSwNP), including inconsistent use of assessment tools, common questions concerning biologic therapies, and gaps in shared decision-making. Clinicians often struggle with selecting appropriate treatment for individual patients, treatment timing, and communication, while patients report limited understanding of biologics. Through interactive, case-based learning, this program fosters collaboration between allergists and otolaryngologists, aiming to improve treatment consistency, patient satisfaction, and long-term outcomes in CRSwNP care.

Learning Objectives:
Upon completion of this educational activity, participants should be able to:

  • Implement both subjective and objective measures in the evaluation and assessment of patients with CRSwNP 
  • Select treatments for patients with CRSwNP based on individual patient characteristics and available evidence
  • Implement strategies to overcome barriers to the optimal use of biologics in the treatment of patients with CRSwNP

KEY DATES

Event Start Date
06 Jan, 2026
Event Start Date
Event End Date
06 Jan, 2026
Event End Date
Credits

Integrity CE, LLC designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • 1 AMA PRA Category 1 Credit™
  • TARGET AUDIENCE

    PhysicianOtorhinolaryngologists

    SPECIALITIES

    Chronic DiseasesPharmacy and MedicineOtorhinolaryngology

    RELATED CONFERENCES & LIVE WEBINARS

    Webcast

    Chronic Diseases
    12 CME Hours
    More actions
    US$695

    Webcast

    Ophthalmology
    2.5 AAPA
    More actions
    US$299

    Apr 04, 2022 - Nov 30, 2026 | Webcast

    State required course for Alabama ...
    6 AMA PRA Category 1 Credits™
    ...
    More actions
    US$246